Diabetic nephropathy (DN) is the leading cause of end-stage renal disease and affects an estimated 150 million people worldwide.
Diabetic nephropathy (DN) was discovered by the British physician
Clifford Wilson (1906 Wilson ( -1997 and the German-born American physician Paul Kimmelstiel (1900 Kimmelstiel ( -1970 . Their first publication reporting the disease came out in 1936. 1 Overt nephropathy secondary to glomerular disease usually occurs 15-25 years after the diagnosis of diabetes. In the past, it affected 25-35 % of type 1 diabetic patients under the age of 30 years, but the prognosis of these patients has recently improved. 2 The main issue today is type 2
diabetes. Approximately 2 % of type 2 diabetic patients develop both macroalbuminuria and end-stage kidney disease. 3 Nephropathy in type 2 diabetes has become the most common cause of chronic kidney failure and end-stage kidney disease in the world.
Approximately 50 % of patients admitted for renal replacement therapy have type 2 diabetes. The progressive increase seen in the past has stabilised in recent years at this high level. The basic problem is the high prevalence of type 2 diabetes in the developed world. The
International Diabetes Federation predicts an 75 % increase in the worldwide incidence of diabetes. This would mean that, by 2025, 324 million people would be diabetic. Thus, the expected number of DN cases is huge.
Optimal treatment of diabetes, especially glycaemic and blood pressure control, have markedly improved renal prognosis in the past decade. Any antihypertensive therapy reduces renal damage and delays the decline of glomerular filtration rate (GFR). 4 Due to the progressive nature of DN, treating the disease is challenging. Current first-line therapies include lowering of blood pressure plus blockade of the renin-angiotensin-aldosterone system (RAS) with angiotensin converting enzyme (ACE)-inhibitors and/or angiotensin receptor blockers (ARBs). These treatments reduce proteinuria and delay the time to end-stage renal disease (ESRD) in patients with type 1 and type 2 diabetic nephropathy. [4] [5] [6] [7] [8] However, the therapeutic efficacy of this approach is limited and suboptimal. 9 Of particular concern is the phenomenon of 'late escape', i.e., the recurrence of proteinuria despite continued RAS blockade. 5 But the most pressing problems are the incomplete reduction of proteinuria and the failure to completely block GFR loss, warranting additional interventional strategies. In this context, an activated endothelin (ET) system may contribute to the progression of DN. 5 myocardial growth and inflammation. 7, 8 The initial stages of DN involve subtle morphologic changes in the renal glomeruli, with progression to microalbuminuria, macroalbuminuria and, ultimately, ESRD.
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The ET system plays an important role in the pathophysiology, not only of cardiovascular disease but also of renal disease. In DN, the ET system is overactive, as indicated by the elevated plasma and urinary ET-1 levels found in patients. 16 Increased plasma ET-1 concentrations found in type 2 diabetes patients correlate with the severity and duration of diabetes. 17, 18 Importantly, in diabetic patients with nephropathy, raised levels of ET-1 also correlate with reduced renal function, increased blood pressure and albuminuria. 18 Insulin increases renal ET expression, which may be especially relevant in diabetics with insulin resistance in an earlier phase of the disease when higher insulin concentrations occur.
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Role of Endothelin Receptor Antagonists in Experimental Diabetic Nephropathy
After the groundbreaking discovery of the endothelial-cell-derived vasopressor agent ET by Yanagisawa et al., 6 inhibitors of the ET receptor were high on the priority list of the pharmaceutical industry.
After various promising experimental trials, clinical studies in various pathologies with an assumed pathophysiological role of ET were conducted. 20, 21 Although several were disappointing, we increasingly learned from these trials -mainly from the side effects. In patients with heart failure, high doses of bosentan and darusentan were investigated.
Although pulmonary and systemic haemodynamics were improved, the overall outcome was negative because of increases in morbidity and mortality, mainly due to volu me overload. As a result, the treatment of cardiovascular disease with ET receptor antagonists was abandoned. 20, 21 On the other hand, in one specific condition, i.e., pulmonary arterial hypertension, several clinical trials yielded positive results, leading to a well-defined indication for this class of drugs.
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Another attractive target was renal disease. The various renal effects of ET had led to the hypothesis that ET receptor antagonists were presumably renoprotective. 16 Learning from the experiences in pulmonary arterial hypertension, and in contrast to congestive heart failure, many investigators were convinced that renoprotection was provided not by the haemodynamic effects of ET receptor antagonists, but rather by their anti-inflammatory and antiproliferative effects. This led to several studies with the goal of protecting the kidney in diabetic and non-diabetic nephropathies.
Various studies have shown marked beneficial effects of ET receptor
antagonists in animal models of diabetes and, although these models are limited in terms of their comparability with the human kidney, they still helped us understand the mechanisms of these beneficial effects.
Among a great number of experiments, two experimental studies which had led to the hypothesis of renoprotection by ET blockade will be discussed in more detail here. In the trial by Gagliardini et al., 23 streptozotocin diabetic rats were uninephrectomised and treated with an ACE-inhibitor (lisinopril) and ETA-antagonist (avosentan), or both.
Therapy with both lisinopril and avosentan normalised proteinuria, prevented tubulointerstitial damage and induced a regression of glomerular lesions. Interestingly, while only partial renoprotection was achieved by each drug alone, the two drugs, which both reduced proteinuria, affected different renal targets: lisinopril improved pathological glomerular size selectivity to large macromolecules, whereas avosentan ameliorated peritubular capillary architecture and reduced interstitial inflammation and fibrosis. 23 In a recently published trial conducted by Zoja et al., Zucker diabetic fatty rats were treated orally with an ACE-inhibitor (ramipril), with an ETA-antagonist (sitaxsentan) or with both. 24 In this setting, the antiproteinuric effects could mainly be attributed to the ACE-inhibitor.
However, the ETA-antagonist had important effects on cardiac structure, mitochondrial damage and microvascular architecture, mainly through blocking the effects of VEGF-1.
Several other experimental trials have been published in the past decade, all of which suggest a nephroprotective effect of ET receptor antagonists alone and/or in combination with a blocker of the RAS. 
Role of Endothelin Receptor Antagonists in Clinical Diabetic Nephropathy
Encouraged by experimental data and by a promising pilot trial, we performed a multicentre study in more than 50 European centres (the SPEED II trial). 26 The study population comprised 286 patients with DN In all three trials, GFR was unchanged after treatment with the respective ET receptor antagonist.
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What Can We Learn from these Three Important Clinical Trials?
There is no doubt that the ET receptor antagonists studied in the three trials -i.e., avosentan and atrasentan -dramatically reduce proteinuria and thus are likely to be highly nephroprotective.
However, their use in this setting is currently still limited by their side effects -mainly fluid overload.
When we compare the effects and side effects of the two drugs in the three trials, it is evident that lower doses of both avosentan and atrasentan are antiproteinuric, with a low rate, if any, of side effects.
In contrast, with higher doses (i.e., 25 and 50 mg avosentan and 1.75 mg atrasentan), a significant rise in the frequency of side effects is seen without any relevant additive antiproteinuric effect (see Figure 1 ). [26] [27] [28] Fluid overload becomes increasingly significant, especially in patients with advanced disease such as those studied in the ASCEND trial (CKD IIIb). Whether low dietary sodium and/or a adequately dosed diuretic regimen will be effective remains to be seen. We believe that these treatments are mandatory when any drug that causes fluid retention is given.
We know from experimental trials that ET promotes sodium excretion, mainly via ETBs at the level of the collecting duct. 29 Consequently, when ET receptor antagonists are used that also block the ETB, at least partially, sodium retention will be a major concern. In fact, in healthy volunteers, the administration of avosentan for one week reduced sodium excretion and increased body weight for one to two days, but body weight subsequently normalised, presumably with the onset of compensatory mechanisms. 30 Furthermore, it has been postulated that ET has a sodium-independent effect on vasopressin-dependent excretion of electrolyte-free water. 29 While, in the atrasentan study by Kohan et al., the drug had no significant effect on body weight, the lowering of haemoglobin levels suggested an internal fluid shift -i.e., redistribution of fluid into the vascular compartment. 28 In clinical practice, patients treated with ET receptor antagonists, particularly if their GFR is markedly reduced, should be advised to reduce sodium intake and should also be given adequate doses of diuretics -keeping in mind that, in proteinuric patients, the dose-response relationship is altered because of intratubular protein binding of diuretics. It is worthwhile looking beyond renoprotection. Even a minor reduction of renal function is associated with a dramatic increase in non-fatal and fatal cardiovascular events. In this context, again, ET receptor antagonists are of considerable interest: in the heart, they improve cardiac structure and microvascular architecture and reduce mitochondrial damage, and in the vasculature they reduce vascular remodelling and vessel wall hypertrophy, at least under experimental conditions. 24, 32 Apart from their renoprotective properties, ET receptor antagonists will also be welcome because a significant proportion of patients with CKD also have cardiac problems and resistant hypertension, which will justify the use of ET receptor antagonists as additional antihypertensive and (potentially) somewhat cardioprotective agents. 33 In many discussions, the following issues have been raised: should ET receptor antagonists be abandoned because of their side effects?
Do the potential problems with fluid overload negate the beneficial [26] [27] [28] effects on renal and myocardial tissue? Would more selective ET receptor antagonists with a higher affinity for the ETA be equally renoprotective but induce fewer side effects?
Although we do not have the evidence-based answers to all these questions, the overwhelmingly positive findings in experimental studies are promising and should encourage the continuation of well-designed trials that take into consideration the selection of the right dose and of an appropriately subclass-specific ET receptor antagonist. Such studies should be performed in well-defined populations, excluding patients with major pre-existing cardiac problems (mainly heart failure). The study protocols should include advice on how to achieve low dietary sodium intake, possibly the co-administration of diuretics that are active in the collecting duct, and a strict weight-gain control. Beyond such indispensable clinical studies, we also need additional experimental data on the role of ET-receptor subtypes in the kidney, especially in the collecting duct. 31 We are convinced that, in future, ET receptor antagonists will have a role to play in patients with renal and reno-cardiac disease.
Predictably, the benefit will be greatest if these drugs are used at earlier stages of renal disease than in the above studies, mainly because, at these earlier stage, fluid retention is less of a problem.
Betablockers, once contraindicated in heart failure patients because of their side effects, are now the cornerstone of therapy. Maybe one day ET receptor antagonists will know the same fate? n Endothelin Receptor Antagonists in Diabetic Nephropathy
